Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
Trial details
- Registry ID
- NCT04140695
- Phase
- Phase 3
The FDA approved Tradipitant (Nereus) on 30 Dec 2025.
Drug identity checked against registry records
Also recorded as Nereus; VLY-686
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2025-12-30Day | Tradipitant | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA220152", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["NEREUS"], "active_ingredients": ["TRADIPITANT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20251230", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |